// App-Quantinova.ai

5059 : Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Sunil Parimi

Principal Investigators

  • Bernhard J. Eigl

  • Katherine Sunderland

  • Muhammad Zulfiqar

  • Daygen L. Finch

  • Conrad D. Oja

  • Joanna Vergidis

  • Leanne Chung-Yan Seto

  • Arun Azad

  • Martin Gleave

  • Kim N. Chi

Medical Centers

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • BC Cancer Agency, Vancouver, BC, Canada

  • BC Cancer Agency, Abbotsford, BC, Canada

  • British Columbia Cancer Agency, Southern Interior Centre, Kelowna, BC, Canada

  • British Columbia Cancer Agency, Abbotsford Centre, Vancouver, BC, Canada

  • BC Cancer Agency Vancouver Island Centre, Victoria, BC, Canada

  • Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic castration-resistant prostate cancer

  • Depression

  • Solid malignancies

Biomarkers

  • Apoptotic body index

Drug/Treatment

  • Enzalutamide

  • CB-7598

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02125357

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved